NEXSTAR DAUNOXOME RECOMMENDATION FOR FIRST-LINE USE IN ADVANCED KAPOSI's SARCOMA BOOSTED BY RANDOMIZED TRIAL; EFFICACY AND TOXICITY COMPARABLE TO ABV
Executive Summary
NeXstar's randomized trials for its liposomal daunorubicin DaunoXome in advanced AIDS-related Kaposi's sarcoma may set a precedent for AIDS therapies to follow. Based on the results of the studies, eight members of FDA's Oncologic Drugs Advisory Committee voted June 8 to recommend DaunoXome as a first-line therapy for advanced KS.